Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
2015 ◽
Vol 3
(Suppl 2)
◽
pp. P145
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. e16071-e16071
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 5040-5040
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. e15079-e15079
2015 ◽
Vol 33
(15_suppl)
◽
pp. TPS5072-TPS5072
◽
Keyword(s):
2016 ◽
Vol 15
(13)
◽
pp. e1645-e1646
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 5074-5074
Keyword(s):